Cancer Family
Uveal Melanocytic Neoplasm
CI-CAN-00000381Explore in graph →
Non-malignant59 active trials1 approved drugs17 evidence items
- NCIt
- C205057
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000381Explore in graph →
Clinical trials
232 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma(NBM-BMX-UM) | recruiting | Phase 1 / Phase 2 | 36 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Nov 28, 2025 |
| clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | active not recruiting | — | 1,150 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05893654 | Melphalan Chemoreduction for Ocular Melanoma(MELCOM) | enrolling by invitation | Phase 1 / Phase 2 | 10 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04283890 | PHP and Immunotherapy in Metastasized UM(CHOPIN) | active not recruiting | Phase 1 / Phase 2 | 83 | Leiden University Medical CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT04424719 | Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)(SALOME) | recruiting | N/A | 700 | Institut CurieOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT05315258 | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma(TebeMRD) | active not recruiting | Phase 2 | 850 | University of OxfordOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT07063875 | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression(SILVER) | recruiting | Phase 1 / Phase 2 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT05502900 | Adjuvant Melatonin for Uveal Melanoma(AMUM) | recruiting | Phase 3 | 100 | Gustav StalhammarOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06863870 | Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma | active not recruiting | — | 35 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06519266 | PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases(SCANDIUM-III) | recruiting | Phase 3 | 40 | Vastra Gotaland RegionOTHER_GOV | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | active not recruiting | Phase 3 | 30 | Delcath Systems Inc.INDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04729543 | MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer(MC2TCR) | recruiting | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT05733728 | Retrospective Register for Uveal Melanoma | recruiting | — | 1,400 | Medical University of ViennaOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT01438658 | Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma(UM) | recruiting | — | 250 | Hadassah Medical OrganizationOTHER | 1 | Sep 28, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Dec 4, 2025source: clinicaltrials